sunRIZE
65 evidence topics · 15 sources
Objective
Objective and population stated by the company
Relevance of the congenital HI trial to tumor HI stated by the company
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2024-01-11” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-11-14” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-11-14” (opens the source at this quote in a new tab)
“First Posted 2024-01-17” (opens the source at this quote in a new tab)
“Last Update Posted 2026-01-08” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
| Country | Locations listed in the record |
|---|---|
| United States | “Philadelphia, Pennsylvania, United States, 19104”; “Fort Worth, Texas, United States, 76104” |
| Bulgaria | “Varna, Bulgaria, 9010” |
| Denmark | “Odense, Denmark, 5000” |
| France | “Bron, France, 69677”; “Paris, France, 75015” |
| Georgia | “Tbilisi, Georgia, 0159” |
| Germany | “Berlin, Germany, 13353”; “Düsseldorf, Germany, 40225” |
| Greece | “Athens, Greece, 115 27” |
| Oman | “Seeb, Oman, 123” |
| Qatar | “Al Rayyan, Qatar” |
| Spain | “Barcelona, Spain, 08035”; “Seville, Spain, 41013” |
| Turkey (Türkiye) | “Ankara, Turkey (Türkiye), 06800” |
| United Kingdom | “London, United Kingdom, WC1N 3JH”; “Manchester, United Kingdom, M13 9WL” |
| Vietnam | “Hà Nội, Vietnam, 100000” |
Countries and U.S. enrollment stated by the company
Completion of enrollment
Announcement of topline results
Study design
Design in the ClinicalTrials.gov record
Randomization scheme and open-label infant arm in the ClinicalTrials.gov record
Treatment periods and open-label extension in the congress presentation
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Body mass index exclusion in the ClinicalTrials.gov record
Key inclusion criteria in the congress presentation
“Ages 3 months – 45 years” (opens the source at this quote in a new tab)
“Biochemically established diagnosis of cHI” (opens the source at this quote in a new tab)
“Persistent hypoglycemia despite SoC” (opens the source at this quote in a new tab)
“SMBG: >3 hypo (<70 mg/dL) per week” (opens the source at this quote in a new tab)
“CGM: >8% avg daily time <70 mg/dL” (opens the source at this quote in a new tab)
Treatment
Treatment arms in the ClinicalTrials.gov record
Dose, schedule, and background therapy stated by the company
Route and infusion duration of ersodetug
Dosing in the open-label extension
Study outcomes
Rationale for using weekly hypoglycemia events by self-monitored blood glucose as the primary endpoint
Primary outcome in the ClinicalTrials.gov record
Key secondary outcome in the ClinicalTrials.gov record
Primary and key secondary endpoints stated by the company
Other glycemic outcomes in the ClinicalTrials.gov record
Safety outcomes in the ClinicalTrials.gov record
Limitations of self-monitored blood glucose metrics acknowledged by the FDA
Unblinded self-monitored glucose as a source of bias stated by the company
Glucose monitoring as both safety tool and endpoint in an ambulatory trial
Key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring
Contrast with the inpatient glucose infusion rate endpoint of the tumor HI trial
Statistical analysis description
Number of participants (Planned and analyzed)
Planned power for the primary endpoint
Planned and actual enrollment stated by the company
Participants in the per protocol set
Description of analysis sets
Analysis window and effect measure
Pre-specified, post-hoc, and sensitivity analyses submitted to the FDA
Full analysis set
No evidence found.
Results
Participant disposition
Completion of the controlled period and entry into the open-label extension
Retention in the open-label extension, January 2026
Retention in the open-label extension, June 2026
Retention in the open-label extension, September 2026
Treatment duration in the open-label extension, November 2026
Planned conclusion of the open-label extension
Baseline characteristics
Demographics, background therapy, and baseline glycemia of the enrolled population
Preliminary baseline summary reported in November 2025
“Average age of 3.4 years (range: 3m – 15y)” (opens the source at this quote in a new tab)
“Average of 15 hypoglycemia events/week by SMBG” (opens the source at this quote in a new tab)
“40% on DZ” (opens the source at this quote in a new tab)
“67% on SSAs” (opens the source at this quote in a new tab)
“13% had previous pancreatectomy” (opens the source at this quote in a new tab)
Efficacy results
Primary endpoint: weekly hypoglycemia events by self-monitored blood glucose not met
Key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring not met
Percent time in hypoglycemia by continuous glucose monitoring at earlier time points, full analysis set
Percent time in hypoglycemia by continuous glucose monitoring, per protocol set
Pre-specified and post-hoc continuous glucose monitoring endpoints
Drug concentrations and insulin biomarker response
Preliminary open-label extension observations
FDA Type B meeting on the efficacy results, March 2026
FDA review of the submitted datasets and pre-BLA recommendation, October 2026
Timing of the pre-BLA meeting and possibility of a further randomized study
Possible effect of the sunRIZE results on the FDA assessment of the tumor HI trial
Health-related quality of life and patient-reported outcomes
Patient-reported quality of life outcomes under evaluation
Patient and family experience in the open-label extension
Safety results
Overall adverse events and adverse drug reactions
Study limitations
Summary
- Population: sunRIZE enrolled participants with congenital hyperinsulinism aged 3 months to 45 years, a different disease and a younger population than adults with tumor hyperinsulinism, so its efficacy results are indirect evidence for this report. Its main relevance here is the safety data and its effect on the regulatory assessment.
- Outcome: the trial did not meet its primary or key secondary endpoint. The favorable continuous glucose monitoring results at earlier time points and in the per protocol set are nominal, and the company's explanation of the result (self-monitored measures confounded by functional unblinding through real-time glucose monitoring) is its own interpretation.
- Reporting: results are available only from company releases, filings, and congress slides, with no peer-reviewed publication. Sources differ on the number of discontinuations for hypersensitivity (2 serious reactions in the topline release; 3 participants in the congress slides; 4 early terminations in the January 2026 presentation), on the CGM result at 10 mg/kg (“approximate 25% reduction” against “-32%; p=0.30”), and on hypertrichosis (36% and about 35%). One baseline cell reads “12 (66%)” for 12 of 20 participants. The registry still lists an estimated enrollment of 56.
- The open-label extension is ongoing, and its glycemic observations are described by the company as preliminary.